Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03003949
Other study ID # 16-1731
Secondary ID 1R01MH108690-01A
Status Terminated
Phase Phase 4
First received
Last updated
Start date January 24, 2017
Est. completion date May 10, 2020

Study information

Verified date March 2020
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Women in the menopause transition ('perimenopause') are exposed to extreme hormone variability, tend to experience a unique set of severe stressors (e.g., divorce, death of loved ones), and are also at substantially elevated risk to suffer from mood and anxiety disorders. The purpose of this research is to understand the mechanisms by which variability in estradiol (E2) is associated with the symptoms of anxiety and anhedonia (loss of interest and pleasure - a common symptom of depression). By stabilizing E2 variability with a hormonal manipulation, this research will determine the degree to which the E2 variability (or E2 levels) plays a causal role in perimenopausal anxiety and anhedonia symptoms and whether it does so by affecting biological responses to stress.


Description:

Framed within a diathesis-stress model, the primary objective of this research is to determine the pathophysiological mechanisms of estradiol (E2) in the clinical anxiety and anhedonia seen in the menopause transition (MT). Specifically whether E2 variability or E2 levels predict exaggerated hypothalamic-pituitary-adrenal (HPA) axis reactivity and impaired recovery to stress and, in turn, deficits in behavioral indices of threat responsivity and approach motivation and symptoms of anxiety and anhedonia. The secondary objective of the research is to use a hormonal manipulation as a mechanistic probe to stabilize E2 variability in premenopausal ranges and determine if: a) HPA axis reactivity/recovery represents a biomarker of behavioral and symptom responses to E2 stabilization; b) whether recent severe life stress predicts the HPA axis response to hormone stabilization. A total of 170 women in the early or late MT who are eligible for the hormonal probe will be recruited to reflect the full continuum of anxiety and anhedonia symptoms based on self-report to the State-Trait Anxiety Inventory and the Snaith-Hamilton Pleasure Scale, respectively. However, the investigators will over-represent the clinically impairing end of the anxious and anhedonic phenotype (75% of the sample). Over an 8-week baseline, anxiety and anhedonia symptoms and serum E2 measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) will be assessed on a weekly basis. At baseline week 8, HPA axis (plasma cortisol and ACTH) response to the Trier Social Stress Test and behavioral measures of threat responsivity (via Dot-Probe task) and approach motivation (Effort Expenditure for Rewards Task 'EEfRT') will be determined. Using transdermal E2 as a pharmacological probe to stabilize variability of E2 in premenopausal ranges, women will then be randomized to transdermal E2 (0.10 mg) or placebo for 16 weeks. This is not a clinical efficacy trial. The investigators will use an randomized control trial (RCT) design with a hormonal manipulation in order to investigate the pathophysiologic role of E2 variability (or E2 levels) in HPA axis dysregulation and, in turn, threat responsivity and approach motivation. Serum E2 will be assessed weekly during weeks 9-16, and HPA axis reactivity to stress and behavioral responses to the Dot-Probe and EEfRT tasks will be assessed every four weeks during the 16 week probe.


Recruitment information / eligibility

Status Terminated
Enrollment 82
Est. completion date May 10, 2020
Est. primary completion date May 10, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 45 Years to 60 Years
Eligibility Inclusion Criteria: - Perimenopausal (either early perimenopause, defined as menstrual cycle length 7+ days longer or shorter than usual; or the late perimenopause, defined as =2 skipped cycles and an interval of amenorrhea =60 days but within one year of the last menstrual period) - 45 to 60 years of age - must be medically healthy Exclusion Criteria: - a history of cardiovascular disease (CVD) including coronary artery disease, arteriosclerosis, heart attack, or stroke - Type I or II diabetes - personal history of thrombotic events - personal or family history suggesting elevated risk for E2-related cancer - currently experiencing migraine headaches with aura

Study Design


Intervention

Drug:
Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release
Transdermal Estradiol worn daily for 16 weeks (patch changed every 7 days).
Placebo Patch
Matching placebo patches to be worn every day for 16 weeks (patch changed every 7 days).
Progesterone Capsule
Micronized progesterone (200 mg) will be administered every day for 12 days during the 9th week of randomization and again following randomization at the 17th week
Placebo Oral Capsule
Matching placebo capsules will be administered orally every day for 12 days during the 9th week of randomization and again following randomization at the 17th week.

Locations

Country Name City State
United States Susan Girdler, PhD, Principal Investigator Chapel Hill North Carolina
United States UNC SHARRP Lab Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change Over Time in the Anxiety Score From State-Trait Anxiety Inventory The State-Trait anxiety inventory is consists of 20 questions on a 4-point force-choice Likert-type response scales (scores 0 - 3). The 20 questions are summed together for final score. The score can range from 0 to 60 with higher scores representing higher levels of anxiety. Change over time is defined as the difference in the least square means between timepoints and 95% confidence interval limits. Baseline (Week 8), Weeks 16, 20 and 24
Primary Change Over Time in Anhedonia Score From Snaith-Hamilton Pleasure Scale Anhedonia will be assessed using SHAPS scores which range from 14-56, with higher scores corresponding to higher levels of anhedonia. Change over time is defined as the difference in least square means between time points and 95% confidence interval limits. Baseline (Week 8), Weeks 16, 20 and 24
Secondary Change Over Time in AUC Cortisol Stress Response The stress biomarker cortisol (µg/dL) assessed at rest and in response to the Trier Social Stress test (AUC with respect to ground) at baseline (Week 8) and again post-randomization at weeks 16, 20 and 24. Blood serum samples for measuring cortisol are taken at immediately before the Trier Social Stress test and at 10, 20, 30, and 45 minutes post test. Change over time is defined as the difference in least square means between timepoints and with 95% confidence interval limits. Baseline (Week 8), Weeks 16, 20 and 24
Secondary Change Over Time in Threat Bias Score From Dot Probe Task Changes in threat bias scores assessed using Dot Probe task during labs at weeks 8, 16, 20 and 24. The bias measurement protocol consists of 144 trials (48 threat congruent, 48 threat incongruent, 48 neutral presentations). Participants indicate the probe letter via button press. Angry face location, probe location, probe type and actor are all fully counterbalanced in presentation. The threat bias score equals the mean of reaction time on threat congruent from threat incongruent trials. A threat bias scores >0 indicate a bias towards threat, whereas scores <0 mean that the participant is slower to respond to threatening stimuli than neutral stimuli. Reaction times were measured in milliseconds. Change over time is defined as the difference in least square means between timepoints with 95% confidence interval limits. up to 24 weeks
Secondary Change Over Time in Percent of "Hard Task" Choice in EEfRT Effort Expenditure for Rewards Task (EEfRT) measures approach motivation that indexes the willingness to expend effort to obtain monetary rewards under varying conditions of reward probability and magnitude. On each trial, participants choose between an "easy task" and a "hard task" and are presented with information about the probability of winning (i.e., 12%, 50%, or 88%), and the magnitude of the potential reward if they complete the button-press task successfully (range: $1.24 - $4.12). Completion of the easy task requires 30 button presses in 7 seconds using the dominant index finger, whereas completion of the hard task requires 100 presses with the non-dominant "pinky" finger in 21 seconds. The percent of hard task choices is the dependent measure. Change over time is defined as the difference in least square means between time points with 95% confidence interval limits. up to 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT04064151 - A Research Study for Latina Women Undergoing Breast Cancer Treatment N/A
Recruiting NCT04160611 - What Amount of Stress is Enough for a Successful Conception? Phase 3
Completed NCT02947477 - Emotion Tracking Study for Residents N/A
Recruiting NCT05083871 - Cognitive Appraisals and Team Performance Under Stress in Simulated Trauma Care
Active, not recruiting NCT05092542 - Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers N/A
Completed NCT03464955 - VR Usage in Non-Invasive Surgical Sub-Specialty Procedures N/A
Completed NCT06152549 - Online Emotional Response to Completing a Childhood Maltreatment Self-report Scale
Completed NCT04977726 - Resilience Curriculum for Novice Physicians-in-training N/A
Active, not recruiting NCT04545021 - My Health Day by Day (Mi Salud Dia a Dia)
Not yet recruiting NCT05799534 - Post-Coronavirus Disease of 2019 (COVID-19) Rehabilitation Clinics in Saudi Arabia N/A
Not yet recruiting NCT04173559 - Sleep and Tracking Effects in Pregnancy Study N/A
Completed NCT04927845 - StriveWeekly Trial Post-pandemic N/A
Active, not recruiting NCT04950816 - Examining the Feasibility and Acceptability of a Tailored Version of a Mindfulness-Based Intervention (MBI) Among Youth Experiencing Homelessness (YEH) Phase 1
Completed NCT03645005 - A Research Study for Latina Women After Breast Cancer Treatment N/A
Completed NCT04595084 - Remotely Delivered Programs Targeting COVID-19 Stress-Related Depression and Substance Use N/A
Enrolling by invitation NCT06085105 - Caring for Providers to Improve Patient Experience (CPIPE) Trial N/A
Completed NCT05933746 - Sleep Hygiene Intervention on Undergraduate Students' Sleep and Stress N/A
Enrolling by invitation NCT06063174 - Stress & Resilience Study N/A
Completed NCT05304000 - Psychophysiological Effects of Controlled Respiration and Mindfulness N/A
Completed NCT04441632 - Effect of Positive Attitudes on Behavior and Wellness N/A